The St. Petersburg-based biotech company Biocad plans to open research centers for clinical trials in Turkey, Vietnam, Thailand, and Brazil in 2025. This was reported by Iuliia Linkova, the company’s Deputy Director General for Clinical Development and Research, on March 3.
The company intends to initiate a significant number of new clinical research projects covering both original molecules and biosimilars, expecting to enrol at least 6,900 participants.
The Biocad representative noted that in the previous year, the company had conducted 54 clinical trials involving more than 5,400 patients. It is planned to increase this indicator by 48% by the end of 2025. According to forecasts, during the two-year period, the total number of clinical trials held by the company will exceed 80, including projects in the CIS countries, China, Brazil, and some other non-CIS countries.
